APLS Apellis Pharmaceuticals, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$41.03

Period return

+17.24 (+72.47%)

Volume

2026-05-15O $41.03 H $41.03 L $41.03 C $41.03MA5 $41.03MA20 $40.99MA60 $31.19

6M · 110 barsYahoo Finance · USD2025-12-08 → 2026-05-15

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2024. 10. 16.Medium2 years ago
Scotiabank: r Perform
US analyst rating / recommendation change.
2024. 10. 16.MediumBUY2 years ago
William Blair: Outperform
US analyst rating / recommendation change.
2024. 09. 25.LowHOLD2 years ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2024. 09. 23.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $40.92 · 13 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.

Sector: Healthcare